高齢者の認知機能低下を予防するためのジンコビロバ:ランダム化試験
Beth E Snitz1, Ellen S O'Meara, Michelle C Carlson
1Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
JAMA
|December 31, 2009
まとめ
ジンコビロバは,高齢者の認知機能低下を遅らせなかった. この大規模な臨床試験では,ジンコビロバエキスを摂取した患者とプラセボを服用した患者との間の認知老化に違いは認められなかった.
科学分野:
- ゲロントロジーはゲロントロジーの学科です.
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- ジンコビロバ (Ginkgo biloba) は,高齢者の認知健康を改善するための人気のハーブサプリメントです.
- 認知機能に対する長期的な影響については,十分な臨床試験の証拠が不足しています.
研究 の 目的:
- ジンコビロバエキスが高齢者の認知機能低下の速度を遅らせるかどうかを調査する.
- グローバルおよびドメイン固有の認知機能への影響を評価する.
主な方法:
- ジンコの記憶評価 (Ginkgo Evaluation of Memory,GEM) 研究は,ランダム化され,二重盲検され,プラセボ対照試験であった.
- 72歳から96歳までの3069人の参加者は,平均6.1年間,1日2回,ジンコビロバ120mgまたはプラセボを投与されました.
- 認知機能の低下は,改変ミニメンタルステート試験 (3MSE),アルツハイマー病評価スケール (ADAS-Cog),神経心理学的検査を用いて測定されました.
主要な成果:
- すべての測定領域において,ジンコビロバとプラセボ群の間では,認知機能低下の年間比率において有意な差異は観察されなかった.
- 3MSEとADAS-Cogの変化率は,基礎認知状態によって変化したが,治療群の違いを示さなかった.
- 治療効果は,年齢,性別,人種,教育,APOE*E4アレルステータス,またはベースラインの軽度の認知障害によって異なるものではありませんでした.
結論:
- ジンコビロバ抽出物は,1日2回120mgの投与で,高齢者の認知機能低下を軽減する効果を示さなかった.
- 研究結果は,ジンコビロバは,正常な認知能力または軽度の認知障害を有する個人の認知機能低下を予防するのに効果的ではないことを示唆しています.
関連する概念動画
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

